Prevalence of aminoglycoside resistance in 20 European university hospitals participating in the European SENTRY Antimicrobial Surveillance Programme

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 18, Issue 6, 1999, Pages 414-421

  Schmitz, F J ^a,b   Verhoef, J ^a   Fluit, A C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; GENTAMICIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; AUSTRIA; BELGIUM; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; EUROPE; FRANCE; GERMANY; GRAM NEGATIVE BACTERIUM; GREECE; ITALY; KLEBSIELLA; NETHERLANDS; NONHUMAN; POLAND; PORTUGAL; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPAIN; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; SWITZERLAND; UNITED KINGDOM;

AMIKACIN; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; GENTAMICINS; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; SENTINEL SURVEILLANCE; TOBRAMYCIN;

EID: 0032731098     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050310     Document Type: Article

References (16)

1. 1. Dornbusch K, Miller GH, Hare RS, Shaw KJ, and the ESGAR Study Group: Resistance to aminoglycoside antibiotics in gram-negative bacilli and staphylococci isolated from blood. Report from a European collaborative study. Journal of Antimicrobial Chemotherapy (1990) 26:131-144
2. 2. Bengtsson S, Bernander S, Brorson JE, Dornbusch K, Forsgren A, Hallander H, Henning C, Holm S, Malmborg AS, Nilsson L: In vitro aminoglycoside resistance of gram-negative bacilli and staphylococci isolated from blood in Sweden 1980-1984. Scandinavian Journal of Infectious Diseases (1986) 18:257-263
3. 3. European Study Group on Antibiotic Resistance: In vitro susceptibility to aminoglycoside antibiotics in blood and urine isolates consecutively collected in twenty-nine European laboratories. European Journal of Clinical Microbiology (1987) 6:378-385
4. 4. Dornbusch K, Bengtsson S, Brorson JE, Fritz H, Henning C, Kronvall G, Larsson P, Malmborg AS, Thore M, Tärnvik A, Walder M: Susceptibility to beta-lactam antibiotics and gentamicin of gram-negative bacilli isolated from hospitalized patients: a Swedish multicenter study. Scandinavian Journal of Infectious Diseases (1988) 20:641-547
5. 5. Kresken M, Hafner D: Prävalenz der Antibiotikaresistenz bei klinisch wichtigen Infektionserregern in Mitteleuropa. Chemotherapie Journal (1996) 5:225-230
6. 6. De Neeling AJ, Van Leeuwen WJ, Schouls LM, Schot CS, Van Veen-Rutgers A, Beunders AJ, Buiting AGM, Hol C, Ligtvoet EEJ, Petit PL, Sabbe LJM, Van Griethuysen AJA, Van Embden JDA: Resistance of staphylococci in the Netherlands: surveillance by an electronic network during 1989-1995. Journal of Antimicrobial Chemotherapy (1998) 41:93-101
7. 7. Koneman EW, Allen SD, Jandar WM, Schrenkenberger PC, Winn WC: Bacterial resistance to antimicrobial agents. In: Koneman EW, Allen SD, Jandar WM, Schrenkenberger PC, Winn WC (ed): Color atlas and textbook of diagnostic microbiology. Lippincott-Raven Publishers, Philadelphia (1997) pp 786-803
8. 8. Cooke D, Salter AJ, Philipps I: Antimicrobial misuse, antibiotic policies and information resources. Journal of Antimicrobial Chemotherapy (1980) 6:435-443
9. 9. Mouton RP, Glerum JH, Van Loenen AC: Relationship between antibiotic consumption and frequency of antibiotic resistance of four pathogens - a seven-year survey. Journal of Antimicrobial Chemotherapy (1976), 2:2-19
10. 10. Phillips I, King A, Shannon K: Prevalence and mechanisms of aminoglycoside resistance. A ten-year study. American Journal of Medicine (1986) 80, Supplement 6B: 48-55
11. 11. Aubry-Damon H, Legrand P, Brun-Buisson C, Astier A, Soussy CJ, Leclercq R: Reemergence of gentamicin-susceptible strains of methicillin-resistant Staphylococcus aureus: roles of an infection control program and changes in aminoglycoside use. Clinical Infectious Diseases (1997) 25:647-653
12. 12. Pfaller MA, Jones RN, Doern GV, Kugler K, and the SENTRY Participants Group: Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrobial Agents and Chemotherapy (1998) 42:1762-1770
13. 13. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial tests for bacteria that grow aerobically. Approved standard M7-A4. NCCLS, Wayne, PA (1997)
14. 14. Jones RN, Kehrberg EN, Erwin ME, Anderson SC, and the Fluoroquinolone Resistance Surveillance Group: Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centres in the United States. I. Study on the threat of emerging resistances: real or perceived? Diagnostic Microbiology and Infectious Disease (1994) 19:203-215
15. 15. Montie T, Patamasucon P: Aminoglycosides: the complex problem of antibiotic mechanisms and clinical applications. European Journal of Clinical Microbiology (1995) 14:85-87
16. 16. Cox JR, McKay GA, Wright GD, Serpensu EH: Arrangement of substrates at the active site of an aminoglycoside antibiotic 3′-phosphotransferase as determined by NMR. Journal of the American Chemical Society (1996) 118:1295-1301